Global

Newsroom

RSS feed

Media Enquiries

Sharon McHale
Sharon McHale
Senior Director Public Affairs
CSL Limited
Phone: +613 9389 1506
Mobile: +61 409 978 314
Email: sharon.mchale@csl.com.au
45 Poplar Rd, Parkville
Victoria 3052 Australia

27/10/2014
CSL to acquire Novartis’ influenza vaccine business
CSL Limited has today announced an agreement to acquire Novartis’ global influenza vaccine business for US$275 million, which will be combined with CSL’s existing vaccines and pharmaceutical subsidiary, bioCSL. More.

15/10/2014
CSL announces new A$950m share buyback
CSL Limited (ASX:CSL) today announced a new on-market share buyback of up to A$950 million. More.

08/10/2014
CSL announces major manufacturing expansion in Melbourne
CSL Limited (ASX:CSL) today announced a $210 million expansion of its CSL Behring manufacturing site in Broadmeadows (Melbourne) to help meet growing demand for its global critical care therapy, albumin. More.

13/08/2014
Full Year Results announcement for 2013/14
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$1,307 million for the full year ended 30 June 2014, up US$96 million or 8% on a reported basis when compared to the prior comparable period (PCP). The result includes a one-off U.S. antitrust class action litigation settlement. Earnings per share (EPS) grew 11%, benefiting from current and past capital management initiatives. More.

21/07/2014
bioCSL partners with Immucor to distribute global market-leading transfusion testing technology
bioCSL today announced that it has commenced distribution of Immucor Corporation’s global market‐leading “Capture®” technology platform and reagents in Australia and New Zealand. Capture® is an advanced antibody detection technology used in the cross‐matching of blood used for transfusion. More.

11/06/2014
International Medical Journal Publishes bioCSL’s Fluvax® Investigation Findings
The findings of bioCSL’s multi-year investigation into the cause of the unexpected adverse events associated with its Fluvax® influenza vaccine in 2010 were today published in two separate papers in the peer-reviewed journal Vaccine. More.

09/05/2014
CSL Opens Australian Biotechnology Manufacturing Facility
CSL Limited today officially opened the CSL Behring Biotechnology Manufacturing Facility in Broadmeadows, Melbourne. More.

12/02/2014
Half Year Results announcement for 2013/14
CSL Limited (ASX:CSL) today announced a net profit after tax (NPAT) of US$646 million for the six months ended 31 December 2013, up US$21 million or 3% on a reported basis when compared to the prior comparable period (PCP). The result included a one-off U.S. antitrust class action litigation settlement of US$64 million, or US$39 million after tax. More.

>> Prior Archived Newsroom


 

Media Enquiries - CSL Limited
Sharon McHale
Senior Director Public Affairs
Phone: +613 9389 1506
Mobile: +61 409 978 314
Email: sharon.mchale@csl.com.au
45 Poplar Rd, Parkville
Victoria 3052
Australia

Share
LinkedIn Twitter Facebook Google+